---
title: A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less
  Myelotoxic in a Racially Diverse Cohort
date: '2024-09-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39316768/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240925194758&v=2.18.0.post9+e462414
source: Blood
description: A metronomic, low-dose schedule of decitabine and Venetoclax was safe
  and effective in myeloid malignancies with few dose reductions or interruptions
  in an older diverse population. Median OS for AML and TP53 mutated patients was
  16.1 and 11.3 months ...
disable_comments: true
---
A metronomic, low-dose schedule of decitabine and Venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median OS for AML and TP53 mutated patients was 16.1 and 11.3 months ...